Physician profile
George Giannoukos
NPI 1750313995
$610.60
in general payments reported to CMS, 2019-2025
12 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.72 · 2020: $37.63 · 2021: $100 · 2022: $53.63 · 2023: $37.59 · 2024: $205 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $226.47 | 2019-2025 | Collagenase Santyl, Grafix Pl, Regranex |
| Reddress USA, INC. | $110.00 | 2024 | |
| Davol INC. | $75.65 | 2024-2025 | Phasix Mesh |
| Avita Medical Americas, LLC | $36.49 | 2025 | Recell, Permeaderm, Cohealyx |
| Acell, INC. | $26.65 | 2020 | |
| Kci USA, INC. | $23.72 | 2023 | Activ.A.C., Kerramax Care |
| Abbvie INC. | $22.86 | 2024 | |
| Ethicon US, LLC | $20.95 | 2025 | Echelon; Endopath, Echelon Circular, Echelon Endopath |
| Hartmann USA, INC. | $20.10 | 2025 | Zetuvit Plus 10x10 P10 |
| Reapplix INC. | $19.93 | 2022 | |
| Integra Lifesciences Corporation | $16.80 | 2021 | |
| Misonix INC | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Giannoukos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.